Holen Sie sich die Stockscreener-App
22.47
7.15%
1.50
Handel nachbörslich:
22.00
-0.47
-2.09%
Schlusskurs vom Vortag:
$20.97
Offen:
$22.62
24-Stunden-Volumen:
5.40M
Relative Volume:
3.28
Marktkapitalisierung:
$3.56B
Einnahmen:
$1.27M
Nettoeinkommen (Verlust:
$-512.54M
KGV:
-7.5679
EPS:
-2.9691
Netto-Cashflow:
$-422.10M
1W Leistung:
+12.01%
1M Leistung:
+0.81%
6M Leistung:
+67.31%
1J Leistung:
+59.14%
1-Tages-Spanne:
$21.27
$23.46
1-Wochen-Bereich:
$18.93
$23.46
52-Wochen-Spanne:
$10.57
$23.77
Denali Therapeutics Inc Stock (DNLI) Company Profile
Firmenname
Denali Therapeutics Inc
Sektor
Branche
Telefon
(650) 866-8547
Adresse
161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO
Compare DNLI vs VRTX, REGN, ALNY, ARGX, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DNLI
Denali Therapeutics Inc
|
22.47 | 3.33B | 1.27M | -512.54M | -422.10M | -2.9691 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Denali Therapeutics Inc Stock (DNLI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-24 | Eingeleitet | Wolfe Research | Peer Perform |
| 2026-01-07 | Fortgesetzt | UBS | Buy |
| 2025-04-10 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2025-03-07 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Buy |
| 2025-01-07 | Eingeleitet | Robert W. Baird | Outperform |
| 2025-01-03 | Eingeleitet | William Blair | Outperform |
| 2024-12-16 | Hochstufung | Stifel | Hold → Buy |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-10-07 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-12-13 | Eingeleitet | Citigroup | Buy |
| 2023-11-20 | Fortgesetzt | JP Morgan | Overweight |
| 2023-10-24 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2023-09-06 | Eingeleitet | B. Riley Securities | Buy |
| 2023-01-30 | Eingeleitet | SVB Securities | Outperform |
| 2022-12-05 | Eingeleitet | Cowen | Outperform |
| 2022-11-02 | Hochstufung | BTIG Research | Neutral → Buy |
| 2022-11-02 | Eingeleitet | BofA Securities | Buy |
| 2022-06-23 | Eingeleitet | Berenberg | Buy |
| 2021-12-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2021-09-21 | Eingeleitet | Oppenheimer | Outperform |
| 2021-09-01 | Eingeleitet | SMBC Nikko | Outperform |
| 2021-05-18 | Eingeleitet | UBS | Buy |
| 2021-02-26 | Bestätigt | H.C. Wainwright | Buy |
| 2021-02-10 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2020-11-11 | Bestätigt | H.C. Wainwright | Buy |
| 2020-10-16 | Herabstufung | BTIG Research | Buy → Neutral |
| 2020-09-14 | Fortgesetzt | JP Morgan | Overweight |
| 2020-08-20 | Bestätigt | H.C. Wainwright | Buy |
| 2020-03-13 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2020-02-28 | Hochstufung | Wedbush | Neutral → Outperform |
| 2020-02-24 | Eingeleitet | Jefferies | Buy |
| 2020-02-19 | Eingeleitet | Stifel | Hold |
| 2020-01-27 | Hochstufung | Goldman | Neutral → Buy |
| 2019-09-26 | Eingeleitet | Wedbush | Neutral |
| 2019-09-13 | Eingeleitet | Nomura | Buy |
| 2019-08-09 | Eingeleitet | BTIG Research | Buy |
| 2019-06-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-11-15 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-11-12 | Eingeleitet | Janney | Buy |
| 2018-03-12 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2018-01-02 | Eingeleitet | Evercore ISI | Outperform |
| 2018-01-02 | Eingeleitet | Goldman | Neutral |
| 2018-01-02 | Eingeleitet | JP Morgan | Overweight |
| 2018-01-02 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Denali Therapeutics Inc Aktie (DNLI) Neueste Nachrichten
Stifel raises Denali Therapeutics price target on drug approval - Investing.com
Goldman Sachs raises Denali Therapeutics stock price target on FDA approval - Investing.com
Denali Therapeutics Wins FDA Accelerated Approval for AVLAYAH in Hunter Syndrome, Eyes Launch Boost - Yahoo Finance
Early FDA wins: Corcept’s Lifyorli, Denali’s Avlayah - BioWorld MedTech
BTIG raises Denali Therapeutics price target to $38 on drug approval - Investing.com India
Denali Therapeutics Gains FDA Approval for AVLAYAH Therapy - TipRanks
FDA clears Denali (NASDAQ: DNLI) AVLAYAH therapy for Hunter syndrome - Stock Titan
FDA approves Denali’s Hunter syndrome brain therapy AVLAYAH By Investing.com - Investing.com India
FDA approves Denali Therapeutics drug for Hunter syndrome - statnews.com
Oppenheimer raises Denali Therapeutics price target on FDA approval - Investing.com
Denali Therapeutics Inc. announced that its new drug Avlayah will soon be available on the US market after receiving regulatory approval. - Bitget
Denali Therapeutics announces U.S. FDA approval of Avlayah(TM) (tividenofusp alfa-eknm) for treatment of Hunter syndrome (MPS II) - marketscreener.com
Denali Therapeutics Announces U.S. FDA Approval Of Avlayah™ (Tividenofusp Alfa-Eknm) For Treatment Of Hunter Syndrome (Mps Ii) - TradingView
Denali Therapeutics (NASDAQ:DNLI) Shares Gap UpStill a Buy? - MarketBeat
Denali Therapeutics Receives FDA Approval for AVLAYAH™, First New Treatment for Hunter Syndrome in Nearly 20 Years - Quiver Quantitative
Denali Therapeutics Announces U.S. FDA Approval of AVLAYAH™ (tividenofusp alfa-eknm) for Treatment of Hunter Syndrome (MPS II) - Yahoo Finance
US FDA approves Denali's genetic disorder therapy for children - Reuters
Denali stock gains on FDA nod for lead asset (DNLI:NASDAQ) - Seeking Alpha
Bearish Setup: Why is Denali Therapeutics Inc stock going downQuarterly Profit Report & Daily Technical Forecast Reports - baoquankhu1.vn
Published on: 2026-03-22 06:29:27 - baoquankhu1.vn
Aug Shorts: Can Denali Therapeutics Inc withstand a market correction2026 Retail & Step-by-Step Trade Execution Guides - baoquankhu1.vn
Amyotrophic Lateral Sclerosis Market: Strong Pharma Growth Forecast Through 2034 – DelveInsight | Helixmith, Sanofi, Denali Therapeutics, Transposon Therapeutics, GSK, Biogen, Ionis Pharmaceuticals - Barchart.com
EV Market: How sensitive is Denali Therapeutics Inc to inflationProfit Target & Expert Approved Momentum Trade Ideas - baoquankhu1.vn
Denali Therapeutics CEO: 2026 Pivotal With Hunter Syndrome FDA Decision and New TV Trial Readouts - MarketBeat
Transcript : Denali Therapeutics Inc. Presents at Leerink Global Healthcare Conference 2026, Mar-09-2026 03 - marketscreener.com
Price-Driven Insight from (DNLI) for Rule-Based Strategy - Stock Traders Daily
Pharma News: Is Denali Therapeutics Inc stock suitable for long term investing2026 Levels & Weekly Stock Breakout Alerts - baoquankhu1.vn
Holocene Advisors LP Grows Stake in Denali Therapeutics Inc. $DNLI - MarketBeat
1,000,000 Shares in Denali Therapeutics Inc. $DNLI Purchased by Foresite Capital Management VI LLC - MarketBeat
Denali’s Hunter Syndrome Candidate in the Spotlight After REGENXBIO Rejection - BioSpace
Denali Therapeutics Teases April 5 FDA Decision for Tivi as Launch Plans and Pipeline Catalysts Build - MarketBeat
250,000 Shares in Denali Therapeutics Inc. $DNLI Bought by Boxer Capital Management LLC - MarketBeat
Analysts Offer Insights on Healthcare Companies: Denali Therapeutics (DNLI) and Oruka Therapeutics (ORKA) - The Globe and Mail
Denali Therapeutics (DNLI) Is Up 5.1% After Highlighting Tividenofusp Alfa Ahead Of FDA Decision – Has The Bull Case Changed? - Yahoo Finance
DNLI Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Assessing Denali Therapeutics (DNLI) Valuation After A Strong Year Of Share Price Gains - Yahoo Finance
Denali Rises 11.8% Over the Past Month: Should You Buy, Sell, or Keep the Stock? - Bitget
Denali Gains 11.8% in a Month: Buy, Sell or Hold the Stock? - TradingView
Denali Therapeutics Inc. (NASDAQ:DNLI) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
A Look At Denali Therapeutics (DNLI) Valuation After Wider Losses And New US$200 Million Shelf Registration - Sahm
Denali ‘Moving In A Positive Direction’ With FDA Toward Hunter Drug Action Date - Citeline News & Insights
DNLI: Awaiting FDA decision on a novel Hunter syndrome therapy, with broad pipeline and commercial momentum - TradingView
DNLI: Imminent FDA decision and expanding pipeline highlight strong clinical and commercial momentum - TradingView
Denali Therapeutics (NASDAQ:DNLI) Trading Up 6.1%Should You Buy? - MarketBeat
Relmada Therapeutics, Xenon Pharmaceuticals, Dianthus Therapeutics And Other Big Stocks Moving Higher On Monday - Benzinga
How Denali Therapeutics Inc. stock reacts to global recession fearsPortfolio Risk Report & Stock Market Timing Techniques - Naître et grandir
DNLI Posts Narrower-Than-Expected Q3 Loss, Advances MPS IIIA Drug - MSN
(DNLI) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Denali Therapeutics (DNLI) Is Down 8.0% After Wider Losses And New Shelf Filing Has The Bull Case Changed? - simplywall.st
HC Wainwright Issues Positive Forecast for DNLI Earnings - MarketBeat
Rafferty Asset Management LLC Buys 60,624 Shares of Denali Therapeutics Inc. $DNLI - MarketBeat
Finanzdaten der Denali Therapeutics Inc-Aktie (DNLI)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):